Physician profile
Daniel E Berg
NPI 1578636650
$13,658.68
in general payments reported to CMS, 2019-2025
40 companies · $2,970 in 2025
The $2,970 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,127 · 2020: $1,271 · 2021: $1,181 · 2022: $1,970 · 2023: $1,536 · 2024: $1,604 · 2025: $2,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,525 · Travel and Lodging: $1,524 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,525.12 |
| Travel and Lodging | $1,524.38 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,472.27 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan |
| Medical Device Business Services, INC. | $1,250.16 | 2019 | |
| Medtronic Vascular, INC. | $1,200.54 | 2019-2020 | |
| Edwards Lifesciences Corporation | $1,130.06 | 2022-2025 | |
| Biosense Webster, INC. | $920.50 | 2019-2025 | Carto 3, Qdot Micro Catheter, Qdot Micro |
| Novartis Pharmaceuticals Corporation | $628.15 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $532.71 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.34 | 2019-2025 | Jardiance |
| Amgen INC. | $343.94 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $329.25 | 2019-2025 | |
| Allergan, INC. | $245.96 | 2020 | |
| Abiomed | $235.93 | 2020-2025 | Impella |
| Boston Scientific Corporation | $220.52 | 2022-2023 | Watchman Access System |
| Abbvie INC. | $211.72 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $204.53 | 2019-2023 | Lifevest |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.